Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.
Olmsted County
hysterectomy
morcellation
uterine fibroids
uterine sarcoma
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
17
05
2018
revised:
24
10
2018
accepted:
08
11
2018
pubmed:
18
11
2018
medline:
29
10
2019
entrez:
18
11
2018
Statut:
ppublish
Résumé
Minimally invasive hysterectomy may require the use of morcellation to remove the uterus. In the presence of unexpected sarcoma, morcellation risks disseminating malignant cells and worsening survival outcomes. As a consequence, in 2014 the US Food and Drug Administration issued a black box warning against the use of power morcellator for the treatment of uterine fibroids. However, the proportion of unexpected sarcoma at the time of hysterectomy for presumed benign indication remains unclear. The objective of the study was to estimate the incidence of sarcoma among women undergoing hysterectomy for benign indication in Olmsted County, MN, between 1999 and 2013. We conducted a population-based study including all hysterectomies performed for benign indication in Olmsted County women between Jan. 1, 1999, and Dec. 31, 2013. Cases were identified using the medical records-linkage system of the Rochester Epidemiology Project, and data were abstracted by a gynecologist who reviewed the complete medical records of each woman who underwent hysterectomy. An expert pathologist reviewed the pathologic slides of each sarcoma to ensure the accuracy of the diagnosis. Incidences of sarcoma (overall and by type of sarcoma) were estimated both overall and stratified by menopausal status, indication for surgery, and uterine weight as a rate per 100 persons. A total of 4232 hysterectomies were performed during the study period. Among them, we identified 16 sarcomas, of which 11 (69%) were suspected preoperatively and 5 (31%) were unexpected. Of the total number of hysterectomies, 3759 (88.8%) were performed for benign indication. Among those, the incidence of unexpected sarcoma was 0.13% (5 per 3759 [95% confidence interval, 0.04-0.31%]). Uterine fibroids comprised 27.3% of all hysterectomies for benign indication (n = 1025) and was the indication most commonly associated with diagnosis of unexpected sarcoma. The incidence of unexpected sarcoma among surgeries for uterine fibroids was 0.35% (3 of 851) for premenopausal women and 0.57% (1 of 174) for peri/postmenopausal, and all 4 unexpected sarcomas were leiomyosarcoma. The incidence of unexpected sarcoma progressively increased with higher uterine weight with an incidence of 0.03% (1 of 2993) among women with a uterine weight <250 g vs 15.4% (2 of 13) with a uterine weight ≥2000 g. Unexpected uterine sarcoma was low in all women undergoing hysterectomy for benign indication (0.13% or 1 in 752 surgeries) while it was increased in women with uterine fibroids (0.39% or 1 in 256 surgeries). Peri/postmenopausal women, women with large uteri, and age ≥45 years were risk factors for sarcoma.
Sections du résumé
BACKGROUND
Minimally invasive hysterectomy may require the use of morcellation to remove the uterus. In the presence of unexpected sarcoma, morcellation risks disseminating malignant cells and worsening survival outcomes. As a consequence, in 2014 the US Food and Drug Administration issued a black box warning against the use of power morcellator for the treatment of uterine fibroids. However, the proportion of unexpected sarcoma at the time of hysterectomy for presumed benign indication remains unclear.
OBJECTIVE
The objective of the study was to estimate the incidence of sarcoma among women undergoing hysterectomy for benign indication in Olmsted County, MN, between 1999 and 2013.
STUDY DESIGN
We conducted a population-based study including all hysterectomies performed for benign indication in Olmsted County women between Jan. 1, 1999, and Dec. 31, 2013. Cases were identified using the medical records-linkage system of the Rochester Epidemiology Project, and data were abstracted by a gynecologist who reviewed the complete medical records of each woman who underwent hysterectomy. An expert pathologist reviewed the pathologic slides of each sarcoma to ensure the accuracy of the diagnosis. Incidences of sarcoma (overall and by type of sarcoma) were estimated both overall and stratified by menopausal status, indication for surgery, and uterine weight as a rate per 100 persons.
RESULTS
A total of 4232 hysterectomies were performed during the study period. Among them, we identified 16 sarcomas, of which 11 (69%) were suspected preoperatively and 5 (31%) were unexpected. Of the total number of hysterectomies, 3759 (88.8%) were performed for benign indication. Among those, the incidence of unexpected sarcoma was 0.13% (5 per 3759 [95% confidence interval, 0.04-0.31%]). Uterine fibroids comprised 27.3% of all hysterectomies for benign indication (n = 1025) and was the indication most commonly associated with diagnosis of unexpected sarcoma. The incidence of unexpected sarcoma among surgeries for uterine fibroids was 0.35% (3 of 851) for premenopausal women and 0.57% (1 of 174) for peri/postmenopausal, and all 4 unexpected sarcomas were leiomyosarcoma. The incidence of unexpected sarcoma progressively increased with higher uterine weight with an incidence of 0.03% (1 of 2993) among women with a uterine weight <250 g vs 15.4% (2 of 13) with a uterine weight ≥2000 g.
CONCLUSION
Unexpected uterine sarcoma was low in all women undergoing hysterectomy for benign indication (0.13% or 1 in 752 surgeries) while it was increased in women with uterine fibroids (0.39% or 1 in 256 surgeries). Peri/postmenopausal women, women with large uteri, and age ≥45 years were risk factors for sarcoma.
Identifiants
pubmed: 30447212
pii: S0002-9378(18)32111-2
doi: 10.1016/j.ajog.2018.11.1086
pmc: PMC7118695
mid: NIHMS1559423
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
179.e1-179.e10Subventions
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000135
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier Inc.
Références
N Engl J Med. 2016 Mar 10;374(10):986-90
pubmed: 26962735
Eur J Gynaecol Oncol. 2003;24(3-4):237-40
pubmed: 12807231
J Womens Health (Larchmt). 2013 Oct;22(10):807-16
pubmed: 24033092
Gynecol Oncol. 2011 Aug;122(2):255-9
pubmed: 21565389
Mayo Clin Proc. 2012 Dec;87(12):1202-13
pubmed: 23199802
Obstet Gynecol. 2017 Jul;130(1):130-137
pubmed: 28594764
Int J Epidemiol. 2012 Dec;41(6):1614-24
pubmed: 23159830
Obstet Gynecol. 2013 Aug;122(2 Pt 1):233-41
pubmed: 23969789
Gynecol Oncol. 2010 Jan;116(1):131-9
pubmed: 19853898
J Reprod Med. 2007 Nov;52(11):1001-10
pubmed: 18161397
Oncologist. 2015 Apr;20(4):433-9
pubmed: 25765878
Gynecol Obstet Invest. 1996;42(1):35-8
pubmed: 8840176
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD003677
pubmed: 19588344
Int J Gynecol Cancer. 2016 Jul;26(6):1098-104
pubmed: 27177280
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Obstet Gynecol. 2015 Feb;125(2):397-405
pubmed: 25569001
PLoS One. 2012;7(11):e50058
pubmed: 23189178
Clin Obstet Gynecol. 2016 Mar;59(1):103-18
pubmed: 26645385
Cancer. 2014 Oct 15;120(20):3154-8
pubmed: 24923260
JAMA Surg. 2018 Jun 20;153(6):e180141
pubmed: 29641835
Am J Obstet Gynecol. 2005 Dec;193(6):2122-5
pubmed: 16325627
Gynecol Oncol. 2015 Apr;137(1):167-72
pubmed: 25462199
Obstet Gynecol. 2016 Mar;127(3):468-73
pubmed: 26855091
Obstet Gynecol. 2016 Jan;127(1):29-39
pubmed: 26646120
Mayo Clin Proc. 2012 Feb;87(2):151-60
pubmed: 22305027